Cargando…
Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment
INTRODUCTION: This study was designed to gain insight into the treatment experiences and expectations of patients with atrial fibrillation (AF) who were treated with vitamin K antagonists (VKA) or recently switched from VKA treatment to direct oral anticoagulant (DOAC) therapy. Little is known about...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584713/ https://www.ncbi.nlm.nih.gov/pubmed/32462633 http://dx.doi.org/10.1007/s40119-020-00173-8 |
_version_ | 1783599652139958272 |
---|---|
author | Slavenburg, Marcel van den Bent, Janneke H. Barten, Thierry Reijs-Scheijgrond, Margje de Koning, Constance |
author_facet | Slavenburg, Marcel van den Bent, Janneke H. Barten, Thierry Reijs-Scheijgrond, Margje de Koning, Constance |
author_sort | Slavenburg, Marcel |
collection | PubMed |
description | INTRODUCTION: This study was designed to gain insight into the treatment experiences and expectations of patients with atrial fibrillation (AF) who were treated with vitamin K antagonists (VKA) or recently switched from VKA treatment to direct oral anticoagulant (DOAC) therapy. Little is known about the perceptions and expectations of patients with AF who are being prescribed oral anticoagulants (OACs), leading to different expectations of patient and doctor of their respective roles in disease management between the doctor [general practitioner (GP) or cardiologist] and patient on their respective roles in disease management. METHODS: A market research study was conducted consisting of two phases: (1) qualitative research (n = 16) in which in-depth interviews were conducted; and (2) quantitative research (n = 101), using a conjoint analysis. RESULTS: Patients reported that the three most important aspects of OAC treatment were (in order of priority) reduced risk of blood clots/stroke, low bleeding risk, and not having to use a thrombosis service. Only 12% of VKA-treated patients were familiar with DOAC, although 52% were open to switching when presented with a DOAC profile. CONCLUSIONS: GPs and patients are waiting for the other to mention issues surrounding AF treatment such as switching, use of thrombosis service, and number of pills to take first. The perceptions and experiences of patients with AF regarding their disease and treatment highly influence the decisions GPs make, together with these patients, as well as considerations that patients have regarding their treatment; GPs need to be aware of their AF patients’ perceptions and experiences with their condition and medication’ in order to facilitate discussions with patients and improve clinical outcomes. |
format | Online Article Text |
id | pubmed-7584713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-75847132020-10-29 Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment Slavenburg, Marcel van den Bent, Janneke H. Barten, Thierry Reijs-Scheijgrond, Margje de Koning, Constance Cardiol Ther Original Research INTRODUCTION: This study was designed to gain insight into the treatment experiences and expectations of patients with atrial fibrillation (AF) who were treated with vitamin K antagonists (VKA) or recently switched from VKA treatment to direct oral anticoagulant (DOAC) therapy. Little is known about the perceptions and expectations of patients with AF who are being prescribed oral anticoagulants (OACs), leading to different expectations of patient and doctor of their respective roles in disease management between the doctor [general practitioner (GP) or cardiologist] and patient on their respective roles in disease management. METHODS: A market research study was conducted consisting of two phases: (1) qualitative research (n = 16) in which in-depth interviews were conducted; and (2) quantitative research (n = 101), using a conjoint analysis. RESULTS: Patients reported that the three most important aspects of OAC treatment were (in order of priority) reduced risk of blood clots/stroke, low bleeding risk, and not having to use a thrombosis service. Only 12% of VKA-treated patients were familiar with DOAC, although 52% were open to switching when presented with a DOAC profile. CONCLUSIONS: GPs and patients are waiting for the other to mention issues surrounding AF treatment such as switching, use of thrombosis service, and number of pills to take first. The perceptions and experiences of patients with AF regarding their disease and treatment highly influence the decisions GPs make, together with these patients, as well as considerations that patients have regarding their treatment; GPs need to be aware of their AF patients’ perceptions and experiences with their condition and medication’ in order to facilitate discussions with patients and improve clinical outcomes. Springer Healthcare 2020-05-27 2020-12 /pmc/articles/PMC7584713/ /pubmed/32462633 http://dx.doi.org/10.1007/s40119-020-00173-8 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Slavenburg, Marcel van den Bent, Janneke H. Barten, Thierry Reijs-Scheijgrond, Margje de Koning, Constance Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment |
title | Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment |
title_full | Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment |
title_fullStr | Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment |
title_full_unstemmed | Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment |
title_short | Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment |
title_sort | perceptions and experiences of atrial fibrillation patients on their condition and oral anticoagulant treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584713/ https://www.ncbi.nlm.nih.gov/pubmed/32462633 http://dx.doi.org/10.1007/s40119-020-00173-8 |
work_keys_str_mv | AT slavenburgmarcel perceptionsandexperiencesofatrialfibrillationpatientsontheirconditionandoralanticoagulanttreatment AT vandenbentjannekeh perceptionsandexperiencesofatrialfibrillationpatientsontheirconditionandoralanticoagulanttreatment AT bartenthierry perceptionsandexperiencesofatrialfibrillationpatientsontheirconditionandoralanticoagulanttreatment AT reijsscheijgrondmargje perceptionsandexperiencesofatrialfibrillationpatientsontheirconditionandoralanticoagulanttreatment AT dekoningconstance perceptionsandexperiencesofatrialfibrillationpatientsontheirconditionandoralanticoagulanttreatment |